|
Technology patents Cyplasin Biomedical Ltd. has acquired all of the Intellectual Property rights to the Cyplasin protein. The issued patents below currently encompass the present invention as related to a protein having an anti-tumoral effect, a DNA encoding such a protein, as well as its use and a process for the preparation, and the manufacture of such a protein. Our first patent, which describes a “Protein having an anti-tumoral effect,” has been granted as defined below: US Patent No. 6,171,818 B1 was issued January 9, 2001 European Patent EP 0 858 465 was issued January 29, 2003 Japanese Patent NrHei 9-516992 was issued May 20, 2008 A second patent entitled “Cytotoxic Cyplasin of the Sea Hare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive Recombinants” with US-Application No. 10/501,098 and European Application No 02019 914.7-1521 has been granted in the United States. The patent claims cover the production and manufacturing by mammalian cells of a cytotoxic recombinant protein Cyplasin, and its use to treat cancer: US Patent No. 7,271,242 B2 was issued September 18, 2007 Australian Patent Nr2002361168 was issued on May 8, 2008 Applications for these patents have been filed in all relevant countries on a worldwide basis and are expected to be issued as they are processed in due course. |